Abstract
Purpose: To evaluate tumor-specific immunity and define the mechanisms involved in the cryoimmunologic response, we compared the tumor control efficacy and immunologic responses of cryoablation with those of surgical excision in a tumor rechallenge model.
Materials and Methods: Sixty BALB/c mice with RENCA tumors that were generated in the left flank area underwent cryoablation or radical excision. The mice successfully treated were rechallenged with RENCA or an undifferentiated colon carcinoma cell line, CT26, in the contralateral right flank area. The recurrence rate after tumor rechallenge in each group was then observed. To assess the immunologic response of each treatment modality, fluorescent-activated cell sorting (FACS) analysis and a cytotoxicity assay using 51Cr release were performed.
Results: After reinoculation of the RENCA cells, the rate of tumor growth was significantly higher in the surgical excision group than in the cryoablation group (94.4% vs. 11.1%, p=0.001). In the cryoablation group, the tumor growth rate was significantly increased after rechallenge of CT26 cells compared with RENCA (94.1% vs. 11.1%, p=0.001). The cryoablation group showed an elevated CD3, CD4, CD8 T, and natural killer cell count in the FACS analysis and also showed significantly increased cytotoxicity in the 51Cr release assay compared with the excision group.
Conclusions: These results showed that cryoablation, compared to surgical resection, was more effective in preventing tumor growth after rechallenge with RENCA cells and that this response was tumor-specific, because the CT26 cells did not have the same effect.
| Original language | English |
|---|---|
| Pages (from-to) | 834-840 |
| Number of pages | 7 |
| Journal | Korean Journal of Urology |
| Volume | 55 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - 2014 Jan 1 |
Fingerprint
Keywords
- Animal models
- Cryosurgery
- Immunity
- Renal cell carcinoma
ASJC Scopus subject areas
- Urology
Cite this
Tumor-specific immunity induced by cryoablation in a murine renal cell carcinoma model. / Kim, Hyung Keun; Pyun, Jong Hyun; Cho, Seok; Kang, Sung-Gu; Lee, Jeong Gu; Kim, Je-Jong; Cheon, Jun; Park, Hong Seok; Kang, Seok Ho.
In: Korean Journal of Urology, Vol. 55, No. 12, 01.01.2014, p. 834-840.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Tumor-specific immunity induced by cryoablation in a murine renal cell carcinoma model
AU - Kim, Hyung Keun
AU - Pyun, Jong Hyun
AU - Cho, Seok
AU - Kang, Sung-Gu
AU - Lee, Jeong Gu
AU - Kim, Je-Jong
AU - Cheon, Jun
AU - Park, Hong Seok
AU - Kang, Seok Ho
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Purpose: To evaluate tumor-specific immunity and define the mechanisms involved in the cryoimmunologic response, we compared the tumor control efficacy and immunologic responses of cryoablation with those of surgical excision in a tumor rechallenge model.Materials and Methods: Sixty BALB/c mice with RENCA tumors that were generated in the left flank area underwent cryoablation or radical excision. The mice successfully treated were rechallenged with RENCA or an undifferentiated colon carcinoma cell line, CT26, in the contralateral right flank area. The recurrence rate after tumor rechallenge in each group was then observed. To assess the immunologic response of each treatment modality, fluorescent-activated cell sorting (FACS) analysis and a cytotoxicity assay using 51Cr release were performed.Results: After reinoculation of the RENCA cells, the rate of tumor growth was significantly higher in the surgical excision group than in the cryoablation group (94.4% vs. 11.1%, p=0.001). In the cryoablation group, the tumor growth rate was significantly increased after rechallenge of CT26 cells compared with RENCA (94.1% vs. 11.1%, p=0.001). The cryoablation group showed an elevated CD3, CD4, CD8 T, and natural killer cell count in the FACS analysis and also showed significantly increased cytotoxicity in the 51Cr release assay compared with the excision group.Conclusions: These results showed that cryoablation, compared to surgical resection, was more effective in preventing tumor growth after rechallenge with RENCA cells and that this response was tumor-specific, because the CT26 cells did not have the same effect.
AB - Purpose: To evaluate tumor-specific immunity and define the mechanisms involved in the cryoimmunologic response, we compared the tumor control efficacy and immunologic responses of cryoablation with those of surgical excision in a tumor rechallenge model.Materials and Methods: Sixty BALB/c mice with RENCA tumors that were generated in the left flank area underwent cryoablation or radical excision. The mice successfully treated were rechallenged with RENCA or an undifferentiated colon carcinoma cell line, CT26, in the contralateral right flank area. The recurrence rate after tumor rechallenge in each group was then observed. To assess the immunologic response of each treatment modality, fluorescent-activated cell sorting (FACS) analysis and a cytotoxicity assay using 51Cr release were performed.Results: After reinoculation of the RENCA cells, the rate of tumor growth was significantly higher in the surgical excision group than in the cryoablation group (94.4% vs. 11.1%, p=0.001). In the cryoablation group, the tumor growth rate was significantly increased after rechallenge of CT26 cells compared with RENCA (94.1% vs. 11.1%, p=0.001). The cryoablation group showed an elevated CD3, CD4, CD8 T, and natural killer cell count in the FACS analysis and also showed significantly increased cytotoxicity in the 51Cr release assay compared with the excision group.Conclusions: These results showed that cryoablation, compared to surgical resection, was more effective in preventing tumor growth after rechallenge with RENCA cells and that this response was tumor-specific, because the CT26 cells did not have the same effect.
KW - Animal models
KW - Cryosurgery
KW - Immunity
KW - Renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=84916605650&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84916605650&partnerID=8YFLogxK
U2 - 10.4111/kju.2014.55.12.834
DO - 10.4111/kju.2014.55.12.834
M3 - Article
VL - 55
SP - 834
EP - 840
JO - Korean Journal of Urology
JF - Korean Journal of Urology
SN - 2005-6737
IS - 12
ER -